Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized pharmacological treatment for broken heart (takotsubo) syndrome
2022-501874-21-00Phase 4Authorised
- Sponsor
- Region Västra Götaland
- Start
- Nov 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 4, randomised trial of adenosine, dipyridamole and apixaban in Takotsubo cardiomyopathy (TCM) (4 arms), sponsored by Region Västra Götaland. Planned start Nov 2022; status: authorised.
02
Drugs
adenosinedipyridamoleapixaban
03
Conditions
Takotsubo cardiomyopathy (TCM)
Beyond the preview
Go deeper on 2022-501874-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501874-21-00.